rAAV GCDH Gene Delivery for Glutaric Aciduria Neurotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Glutaric aciduria type I (GA-I), such as diet control and carnitine supplementation, are inadequate in reducing 3-hydroxy glutaric acid and glutaconic acid levels, and there is a need for a more effective treatment to address the neurotoxicity caused by glutaryl-CoA dehydrogenase (GCDH) deficiency.
Innovation Solution
Development of a recombinant adeno-associated viral (rAAV) vector containing a codon-optimized GCDH coding sequence and a specially designed promoter, which is delivered to the central nervous system to normalize amino acid metabolism and reduce GA accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If diet control and carnitine supplementation are used to treat GA-I, then GA levels are reduced to some extent, but 3-hydroxy glutaric acid and glutaconic acid levels cannot be eliminated
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver functional GCDH gene copies into patient cells. The viral vector mediates gene transfer across cell membranes, enabling sustained enzyme production without requiring continuous dietary intervention or supplementation.
Solution Approach 2:
The invention changes the fundamental treatment parameter from symptomatic management (diet control, supplementation) to curative gene replacement. By introducing functional GCDH gene, the metabolic pathway parameter is restored, enabling complete elimination of toxic metabolites including 3-OH-GA and glutaconic acid.
2Object-affected harmful factors
If current treatments are applied, then some GA detoxification occurs, but neurotoxicity and neurodegenerative disorders persist
Solution Approach 1:
The patent implements preliminary action by delivering functional GCDH gene before irreversible neurodegenerative damage occurs. Early gene therapy intervention prevents the accumulation of toxic metabolites that cause neuronal damage, rather than attempting to reverse established neurological damage.
Solution Approach 2:
The AAV vector serves as a mediator to deliver the therapeutic gene directly to neural tissues. The viral carrier enables targeted delivery to the central nervous system, ensuring the therapeutic effect reaches the affected neural pathways before permanent damage occurs.
3Reliability
If gene therapy using AAV vectors is implemented, then curative treatment effect is achieved, but treatment complexity increases
Solution Approach 1:
The patent extracts only the essential therapeutic element (GCDH coding sequence) and places it into a simplified AAV vector backbone. By removing unnecessary genomic elements and focusing on the minimal functional requirements, the treatment achieves curative potential while managing complexity through targeted gene delivery.
Data Source
AI summary
The present disclosure relates to codon-optimized sequences coding for hGCDH polypeptide and recombinant adeno-associated virus (rAAV) vectors comprising one of said sequences under the control of a promoter component. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the rAAV vector or the viral particles, and uses thereof in treating Glutaric aciduria type I (GA-I).